Digestive system neoplasm

This phase 2 trial is testing whether giving two drugs before surgery can help people with advanced oral cavity cancer. The drugs, becotatug vedotin and pucotenlimab, are designed to attack cancer cells and boost the immune system. Participants receive three cycles of the combina…

This trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…

This trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…

This trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…

This study tests whether giving the immunotherapy drug dostarlimab for a longer period can completely eliminate tumors in people with a specific genetic type of rectal cancer. Participants have stage II or III rectal cancer that is mismatch repair deficient (dMMR) or microsatelli…

This phase 2 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can completely eliminate early-stage rectal cancer in people whose tumors are microsatellite stable (MSS). Participants receive one infusion of botensilimab followed by b…

This phase II trial tests whether a personalized DNA vaccine, tailored to each patient's tumor, can keep high-risk liver cancer from coming back after surgical removal. Participants who have no remaining signs of cancer after surgery will receive the vaccine plus an immune booste…

This study tests a device that keeps donor livers cool and oxygenated before transplant, aiming to reduce early liver problems. About 215 first-time liver transplant patients will receive a liver preserved with this method. The goal is to see if it lowers the risk of early graft …

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…

This trial is testing whether CRB-701, a targeted chemotherapy that delivers a potent drug directly to cancer cells, can shrink tumors and extend life in people with recurrent or metastatic oropharyngeal (throat or tonsil) cancer. Participants will have already tried platinum-bas…

This trial tests whether a drug called carfilzomib, given directly to the liver through an implanted pump, is safe for people whose colon, adrenal, or bile duct cancer has spread to the liver and persists after prior pump therapy. Participants receive weekly infusions of the drug…

This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…

This phase II trial is testing whether combining the experimental immunotherapy drug ivonescimab with chemotherapy (paclitaxel) delivered directly into the abdomen can safely and effectively treat people with high-grade metastatic appendiceal adenocarcinoma that cannot be removed…

This early-stage trial tests a drug called samuraciclib in 15 people with localized pancreatic cancer that can be surgically removed. Participants will take the drug for about two weeks before their planned surgery. Researchers will check safety and look for changes in tumor cell…

This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …

This phase II trial is testing whether adding an experimental immunotherapy drug called AK112 to a standard chemotherapy regimen (gemcitabine, cisplatin, and albumin-bound paclitaxel) can shrink locally advanced gallbladder tumors enough to allow surgery. Adults with gallbladder …

This study tests whether adding a heat treatment (thermal ablation) to the standard procedure for removing large colon polyps can lower the chance they grow back. About 752 adults will be randomly assigned to receive either standard removal alone or standard removal plus burning …

This trial is testing whether adding ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works better than the usual chemo-immunotherapy combination for people with advanced biliary tract cancer. Ivonescimab is a special antibody that targets two proteins: one that h…

This trial tests whether a home-based prehabilitation program, supported by 5G and artificial intelligence, can help gastric cancer patients prepare for surgery after chemotherapy. The program includes personalized exercise, nutrition, and psychological support, all supervised re…

This trial is testing whether adding a non-invasive ultrasound treatment called histotripsy to the immunotherapy drug durvalumab can strengthen the body's immune response against advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. Histotripsy uses focused sound …

This phase 2 trial is testing whether combining two immunotherapy drugs—vilastobart and retifanlimab—can shrink tumors in people with metastatic pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation. Participants receive both drugs by IV infusion over several months. …

This phase 2 trial is investigating whether adding a ketogenic diet and/or high-dose intravenous vitamin C to standard chemoradiotherapy and immunotherapy can improve outcomes for patients with locally advanced rectal cancer that is mismatch repair proficient (pMMR/MSS). The stud…

This trial tests a new medicine called SOT109 for people with advanced colorectal cancer that cannot be removed by surgery or has spread. SOT109 is designed to find and attack cancer cells that have a specific marker (CDH17) while sparing healthy cells. The study has two parts: t…

This trial asks whether it is safe to skip the routine removal of impacted teeth before radiation therapy for nasopharyngeal carcinoma. Half of the participants will have the extraction as usual, while the other half will not. The study will compare the risk of jaw bone damage (o…

This phase 2 trial tests the safety of belzutifan, a daily oral tablet, in adolescents with rare solid tumors that cannot be surgically removed or have spread. The study includes three tumor types: pheochromocytoma/paraganglioma (PPGL), wild-type gastrointestinal stromal tumors (…

This study tests a combination of an experimental drug (ficerafusp alfa), an immunotherapy (pembrolizumab), and targeted radiation before surgery for people with advanced head and neck cancer that is HPV-negative. About 45 participants will receive these treatments over several w…

This trial compares two endoscopic techniques for removing flat, non-cancerous colorectal polyps that are 10-20 mm in size. One method uses a cold snare (no heat), while the other uses a hot snare with electrocautery. The goal is to see if the cold approach is just as effective a…

This early-stage trial is testing an investigational drug called BL-ARC002 in people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to find a safe dose and to see if the drug shows any signs of shrinking tumors. Participants receive the …

This study tests whether adding an experimental drug called SYS6090 to standard cancer treatments can safely and effectively shrink tumors in people with advanced hepatocellular carcinoma, the most common type of liver cancer. Participants will receive SYS6090 combined with bevac…

This trial tests whether an AI tool called SurgDiff can predict how difficult rectal cancer surgery will be, based on MRI scans and patient data. The goal is to help surgeons choose the best surgical approach for each patient, potentially reducing complications. The study involve…

This trial tests an artificial intelligence system called ADTPS that helps doctors remove early-stage esophageal cancer or precancerous lesions using a scope. The AI analyzes live images during the procedure and overlays a suggested cutting path on the screen. Half of the partici…

This trial tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) to standard chemotherapy before chemoradiation can improve outcomes for people with advanced nasopharyngeal cancer. About 60 adults with non-metastatic, EBV-positive nasopharyngeal carc…

This phase 2 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy (FLOT before surgery, TS-1 after) can improve outcomes for people with resectable gastric or gastroesophageal junction cancer. The study aims to see if this combination increas…

This trial is testing whether artificial intelligence can create 'digital twin' models of esophageal cancer patients to predict how they will respond to a combination of immunotherapy and chemotherapy. The study will compare the AI's predictions against real outcomes in patients …

This trial tests whether giving two immunotherapy drugs—pembrolizumab and cetuximab—before surgery can shrink advanced oral cancers linked to betel-nut chewing. The study enrolls 20 people in the Northern Mariana Islands who have not yet received treatment. Researchers will measu…

This trial tests whether an arginine-free diet, given as a liquid formula for four weeks, can enhance the effects of standard chemoradiotherapy in people with locally advanced rectal cancer. The study first checks the diet's safety in a small group, then randomly assigns about 13…

This trial is testing whether a special type of radiation called radscopal radiotherapy—which combines low-dose radiation to the main tumor and precise high-dose radiation to distant metastases—can enhance the effects of two immunotherapy drugs (sintilimab and ipilimumab) in peop…

This study tests whether an intestinal or multivisceral transplant can help people with a rare abdominal cancer called pseudomyxoma peritonei (PMP) that cannot be removed by surgery. Twenty participants will receive the transplant and be followed for 12 months to see if they surv…

This early-stage trial tests an experimental oral drug called SNV1521, a PARP inhibitor, combined with the RAS-targeting medicine daraxonrasib in adults with pancreatic cancer that cannot be surgically removed or has spread. The main goals are to find safe and tolerable doses of …

This clinical trial is investigating whether an experimental drug called SHR-9839, when used alone or combined with standard chemotherapy and an immunotherapy drug, can help people with advanced esophageal squamous cell carcinoma. The study will include about 84 adults aged 18 to…

This early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…

This phase 2 trial is testing whether giving the immunotherapy drug penpulimab together with chemotherapy before surgery can help people with locally advanced hypopharyngeal carcinoma, a type of head and neck cancer. The study will include about 15 adults aged 18 to 80 with resec…

This phase 2 trial tests whether adding a targeted chemo procedure (TACE) to standard immunotherapy can improve outcomes for people with unresectable liver cancer. About 90 participants will receive either atezolizumab/bevacizumab or durvalumab/tremelimumab plus TACE. The goal is…

This phase 3 trial is testing whether the experimental drug zanzalintinib, alone or combined with an immunotherapy (pembrolizumab plus berahyaluronidase alfa), can improve disease-free survival in people with stage II or III colorectal cancer who have molecular residual disease (…

This phase II trial tests whether choosing chemotherapy based on a specific gene mutation (SMAD4) can improve outcomes for people with pancreatic cancer that is or may be surgically removable. The SMAD4 gene normally acts as a brake on tumor growth, but when it's mutated, tumors …

This phase 2 trial is testing whether combining an experimental immunotherapy (SHR-1701) with a targeted therapy (apatinib) can shrink tumors in people with advanced liver cancer that has progressed after initial treatment. About 80 adults with unresectable or metastatic hepatoce…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This phase 2 trial tests giving short course radiation therapy along with standard chemotherapy before surgery for stomach cancer. The goal is to see if this total neoadjuvant therapy leads to a higher rate of complete cancer disappearance, with fewer side effects than traditiona…

This trial is testing whether an investigational drug called SYS6090, when combined with standard treatments like bevacizumab and chemotherapy, can safely and effectively treat advanced colorectal cancer that cannot be removed by surgery. The study includes adults with a specific…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This study looks at three ways to treat subcapsular hepatocellular carcinoma (HCC), a type of liver cancer near the surface of the liver. It compares two minimally invasive microwave ablation methods—one that avoids piercing the tumor and one that does—against traditional surgica…

This phase 3 trial is testing whether giving targeted therapies that match specific genetic abnormalities in a person's tumor can delay or prevent biliary tract cancer from coming back after surgery. Participants will have their tumor tested for certain markers, and if found, the…

This trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This phase 2 trial is testing a novel combination for people with metastatic pancreatic cancer that has progressed after standard first-line chemotherapy. The approach combines a device that alternately freezes and heats the tumor (multimodal thermal therapy) with a personalized …

This trial tests whether a special light mode called linked color imaging (LCI) helps doctors find more sessile serrated lesions (a type of precancerous colon polyp) during colonoscopy than standard white light. About 2,000 adults aged 45 and older having their first screening co…

This trial is testing whether an experimental drug called MRG007, given together with standard chemotherapy and targeted therapies, can safely shrink tumors in people with advanced colorectal cancer that cannot be removed by surgery. The study involves about 316 participants and …

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This study looks at a new treatment for people with a specific type of advanced stomach cancer (HER2-positive) that has stopped responding to standard therapies. It combines a targeted drug (disitamab vedotin) with immunotherapy and a special type of radiation. The goal is to see…

This early-stage trial is testing an experimental treatment called the IKS04 regimen in people with advanced cancers of the digestive system, including colorectal, stomach, pancreatic, and bile duct cancers. The regimen combines a targeted antibody-drug conjugate with an addition…

This study tests a new planning method called multicompartment dosimetry (MCD) for TheraSphere, a treatment that delivers tiny radioactive beads to liver tumors. The goal is to give a higher radiation dose to the tumor while protecting healthy liver. Researchers will enroll 140 p…

This trial is testing whether a new oral drug called HRS-2329, which blocks multiple RAS proteins, can shrink tumors or slow disease when combined with other anti-cancer therapies. It is enrolling adults with advanced pancreatic cancer that has RAS mutations or amplifications and…

This trial is testing whether transplanting healthy gut bacteria can boost the power of immunotherapy and chemoradiotherapy in people with a common type of locally advanced rectal cancer. Participants receive a combination of sintilimab (an immunotherapy drug), CAPOX chemotherapy…

This trial is testing whether a combination of two newer drugs—envafolimab and suvemcitug—plus chemotherapy delivered directly to the liver can shrink advanced liver tumors enough to allow surgery. The study enrolls adults aged 18–75 with liver cancer that is currently too advanc…

This phase 3 trial tests whether giving the targeted therapy cetuximab plus FOLFIRI chemotherapy in scheduled breaks works as well as continuous treatment for people with a specific genetic type of metastatic colorectal cancer (RAS/BRAF wild-type). The study compares how long the…

This phase II trial is testing whether adding an immunotherapy drug (serplulimab) and a targeted antibody (bevacizumab) to standard chemotherapy can help people with metastatic pancreatic cancer that has progressed after initial treatment. The study enrolls about 34 adults whose …

This early trial is testing an experimental cell therapy called cCTL-GL01 in people with advanced stomach, esophageal, colon, or rectal cancers that have not responded to standard treatments. The therapy uses a patient's own immune cells, which are specially trained in the lab to…

This trial tests whether an artificial intelligence system can tailor the timing of follow-up scans for people who have had liver cancer surgically removed or ablated. Instead of fixed-interval scans every four months, the AI uses routine clinical data to estimate each person's c…

This trial investigates whether ebastine, a widely used allergy medication, can reduce the risk of liver cancer returning after surgery. The study enrolls people with a specific high-risk tumor feature called tumor budding. All participants will take ebastine daily for a year, an…

This phase 2 trial is testing whether giving the immunotherapy drug tislelizumab every 2 weeks or every 4 weeks, alongside standard chemotherapy, is safe and effective for Japanese patients with advanced esophageal cancer that cannot be removed by surgery. The study aims to find …

This umbrella trial is testing whether assigning treatment based on a person's tumor genetics can improve outcomes for advanced biliary tract cancers. Participants receive one of several targeted therapies or immunotherapy, depending on their genetic test results. The study aims …

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This phase III trial is testing whether an experimental drug called BL-M07D1 can slow or stop the growth of advanced colorectal cancer in people whose tumors have high levels of the HER2 protein and who have already tried standard chemotherapy. Participants will be randomly assig…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This study looks at whether combining the targeted drug donafenib with an immunotherapy drug and a liver-directed procedure (either chemoembolization or infusion chemotherapy) can help people with unresectable hepatocellular carcinoma — liver cancer that cannot be removed by surg…

This phase II trial is testing whether adding an experimental drug called retlirafusp alfa to standard chemotherapy and bevacizumab, with or without a short course of radiotherapy, can shrink liver metastases from colorectal cancer enough to allow surgical removal. The study enro…

This trial is investigating whether adding the beta-blocker propranolol to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with resectable locally advanced gastric or gastroesophageal junction cancer. About 49 participants will receive the c…

This trial is testing whether a combination of two drugs—sacituzumab tirumotecan and envafolimab—can shrink advanced biliary tract cancers (cancers of the bile ducts or gallbladder) that have grown despite initial treatment. The study enrolls up to 28 adults whose tumors carry a …

This trial tests a new disposable endoscopic closing device for sealing gastrointestinal tissue and stopping bleeding. About 60 people needing tissue closure during endoscopy will be randomly assigned to receive either the new device or standard metal clips. The study compares ho…

This trial investigates whether adding dapagliflozin—a drug typically used for diabetes—to standard first-line therapy can improve tumor response in people with advanced liver cancer that cannot be surgically removed and who also have metabolic syndrome. About 44 participants wil…

This trial tests whether an artificial intelligence (AI) system can help doctors select the best first-line immune checkpoint inhibitor (ICI) therapy for adults with unresectable hepatocellular carcinoma (HCC), a type of advanced liver cancer. About 1,800 participants across 26 h…

This phase 3 trial is testing whether adding two immune-boosting drugs, iparomlimab and tuvonralimab, to standard chemotherapy can help people with a specific type of metastatic colorectal cancer that has stopped responding to first-line treatment. The study includes about 270 ad…

This early-phase trial is testing an experimental antibody-drug conjugate called MC002 in adults with advanced solid tumors, such as esophageal or lung cancer, that have progressed after standard treatments. MC002 is designed to target a protein found on cancer cells and deliver …

This trial tests whether a combination of whole-body electromyostimulation (WB-EMS) — a technology that uses electrical impulses to make muscles contract — and nutritional therapy can help people with certain gastrointestinal cancers preserve muscle mass. Participants include tho…

This phase 3 trial is testing whether adding a three-month course of FOLFOX4s chemotherapy after short-course radiotherapy improves outcomes compared to radiotherapy alone in adults aged 75 and older with locally advanced rectal cancer. The study aims to see if the combination ca…

This phase 2 trial is testing whether adding zolbetuximab, an antibody that targets a protein called claudin 18.2, to standard chemotherapy can help control advanced or metastatic biliary tract cancers. The study enrolls adults whose tumors overexpress this protein. Participants …

This phase 2 trial is testing whether combining an experimental drug called S-531011 with a precise radiation technique known as RadScopal can help control metastatic colorectal cancer that has not responded to prior treatments. The study enrolls about 30 adults with advanced dis…

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This phase 2 trial is testing whether adding two extra drugs—bevacizumab and sintilimab—to the usual combination of irinotecan and cetuximab can shrink tumors in people with advanced colorectal cancer that no longer responds to irinotecan. The study enrolls 160 adults with RAS wi…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

This phase II trial tests a personalized approach for people with locally advanced esophageal cancer. After initial chemoimmunotherapy, patients whose tumors shrink well go straight to surgery, while those with less response receive additional radiotherapy before surgery. The goa…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This early-phase trial tests an experimental drug called XNW28012 in people with metastatic pancreatic cancer whose disease has worsened after at least one prior treatment. XNW28012 is an antibody-drug conjugate designed to seek out a protein called tissue factor on cancer cells …

This phase II trial tests whether sacituzumab tirumotecan, an antibody-drug conjugate that targets the TROP2 protein, can shrink tumors in people with advanced small bowel adenocarcinoma that has worsened after platinum-based chemotherapy. About 27 adults with this rare cancer wi…

This trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…

This phase II trial tests whether adding an immunotherapy drug (retlirafusp alfa) and possibly a third drug (pertuzumab) to the targeted therapy trastuzumab rezetecan can completely eliminate tumors before surgery in people with locally advanced HER2-positive stomach or gastroeso…

This Phase 3 trial tests whether an experimental drug called QLS31905, combined with chemotherapy (CAPOX), works better than the current immunotherapy drug sintilimab plus the same chemotherapy for people with advanced gastric or gastroesophageal junction cancer. The study includ…

This phase 2 trial tests whether combining the experimental drug tunlametinib with other targeted therapies can shrink tumors or slow cancer growth in people with metastatic colorectal cancer that has worsened after at least one prior treatment. Participants are grouped based on …

This early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess sa…

This trial investigates whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help immunotherapy work better in people with advanced liver cancer. Participants receive either a real transplant via colonoscopy or a sham procedure, alongside standard imm…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…

This phase Ib/II trial investigates whether combining three drugs—two immunotherapies (IBI310 and sintilimab) and a blood-vessel blocker (bevacizumab)—given before and after surgery can improve outcomes for people with resectable hepatocellular carcinoma (liver cancer). The study…

This study tests whether adding an experimental drug called retlirafusp alfa to standard chemotherapy can shrink advanced stomach or gastroesophageal junction cancers enough to allow complete surgical removal. Participants receive the drug combination before surgery, and those wh…

This trial investigates whether raising the body's core temperature to 41.5°C for 4 hours, called whole-body hyperthermia, can improve outcomes when added to standard chemotherapy for people with metastatic pancreatic cancer that has progressed after initial treatment. The study …

This phase 2 trial tests a new drug called ivonescimab (AK112) combined with chemotherapy (irinotecan and cisplatin) for people with metastatic digestive system neuroendocrine cancer that has spread. Some participants also receive a procedure called TACE, which blocks blood flow …

This trial tests a 24-week virtual care program called BRIDGE NET for people with serious mental illness who are starting cancer treatment. The program brings together oncology and mental health teams to plan care, provide early psychiatric support, and regularly check in with pa…

This phase 2 trial tests whether adding ivonescimab—a drug that blocks both PD-1 and VEGF—to standard chemoradiotherapy improves outcomes for people with high-risk nasopharyngeal carcinoma. The study enrolls adults aged 18–65 with previously untreated stage T3N2M0 or stage III di…

This trial investigates whether giving liver cancer patients infusions of their own immune cells, called cytokine-induced killer (CIK) cells, after surgery is safe and feasible. The cells are collected from the patient's blood, grown in a lab, and then returned through six intrav…

This phase II trial tests a combination of three drugs—Becotatug Vedotin, Tislelizumab, and low-dose Lenvatinib—in people with advanced esophageal squamous cell carcinoma whose cancer has progressed after first-line therapy. The study aims to see if this triple therapy can shrink…

This trial investigates whether tailoring treatment based on specific biomarkers can improve outcomes for people with advanced esophageal squamous cell carcinoma that has spread. Participants are randomly assigned to receive either standard chemotherapy plus a PD-1 inhibitor or t…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…

This phase II trial tests a new drug called SKB500 in combination with standard chemotherapy and immunotherapy for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery. The study will evaluate how well the combination shrinks tumors and how sa…

This trial tests whether adding a personalized, ultra-precise radiation technique called PULSAR to standard chemotherapy and immunotherapy is safe for people with esophageal or gastro-esophageal junction cancer. The study aims to find the best radiation dose that can be given wit…

This phase 2 trial tests an experimental drug called SHR-A1904 in people with advanced colorectal cancer that has spread and no longer responds to standard treatments. The study aims to see if the drug is safe and can shrink tumors or slow the disease. Participants must have alre…

This clinical trial tests a new approach for people with a type of bile duct cancer that cannot be removed by surgery. It compares a combination of targeted therapy and a procedure that delivers chemotherapy directly to the liver against standard chemotherapy. The goal is to see …

This phase 2 trial tests an experimental drug called sacituzumab tirumotecan in people with advanced biliary tract cancer whose disease has worsened after at least one prior treatment. The drug is an antibody-drug conjugate designed to seek out and deliver chemotherapy directly t…

This study tests an experimental drug called HSK41959, taken as a tablet, in combination with standard cancer treatments for people with advanced solid tumors that lack a gene called MTAP. The trial includes patients with non-small cell lung cancer, pancreatic cancer, and other a…

This phase II trial tests a combination of two drugs—sacituzumab tirumotecan (a targeted chemotherapy) and tagitanlimab (an immunotherapy)—as a second-line treatment for people with advanced esophageal squamous cell carcinoma or gastric/gastroesophageal junction adenocarcinoma. T…

This pilot study tests whether providing medically tailored meals and fresh produce can help people with stage I-III colorectal cancer eat fewer ultra-processed foods. Participants are randomly assigned to receive fully prepared meals, meals plus fresh produce, or meal-planning m…

This phase 3 trial tests whether adding an experimental drug called cadonilimab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. Cadonilimab is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) …

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This study tests a new approach called photoimmunotherapy for people with locally advanced or borderline resectable pancreatic cancer. Patients receive an injection of ASP-1929, a drug that attaches to cancer cells and becomes active when exposed to a specific light. During surge…

This study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This trial tests a new drug called becotatug vedotin, given together with standard chemotherapy (cisplatin) and radiation, for people with a type of advanced esophageal cancer. The main goals are to find the safest dose and see how well the combination works. About 12 participant…

This trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …

This phase 2 trial tests the drug inavolisib in people with pancreatic ductal adenocarcinoma whose cancer has worsened after prior chemotherapy. The study aims to see if inavolisib can shrink tumors or slow disease progression. Participants take inavolisib daily by mouth, and the…

This observational study follows about 196 adults with early-stage (pT1) rectal cancer who have high-risk features after local tumor removal. Instead of undergoing radical surgery that often requires a colostomy, participants receive adjuvant radiotherapy or chemoradiotherapy. Th…

This phase 2 trial tests whether giving a combination of an immunotherapy drug (serplulimab), an epigenetic drug (decitabine), and chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colorectal cancer. The study enrolls 35 adults with previou…

This trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…

This trial tests whether adding a Chinese herbal formula called Shuganhuazhuo to standard anti-cancer therapy can improve liver function and survival in people with advanced hepatocellular carcinoma (the most common type of liver cancer). The study includes 120 adults who are abo…

This trial investigates whether combining two drugs—trastuzumab deruxtecan (T-DXd) and cetuximab—can shrink tumors in people with advanced colorectal cancer that has low levels of the HER2 protein and has worsened after standard treatments. The study enrolls adults with metastati…

This phase 2 trial tests whether adding the experimental drug HRS-4642 to standard chemotherapy, with or without the immunotherapy adebrelimab, can shrink pancreatic tumors before surgery. The study enrolls adults aged 18-70 with pancreatic ductal adenocarcinoma who have at least…

This phase 3 trial tests whether adding three drugs—SHR-8068, adebrelimab, and bevacizumab—to a standard liver-directed procedure (TACE) can better control incurable hepatocellular carcinoma. About 690 adults with liver cancer that cannot be surgically removed will receive either…

This trial investigates whether using a special ultrasound score (VExUS) to guide fluid delivery during surgery can lower the chance of lung complications in patients aged 65–80 undergoing minimally invasive esophageal cancer removal. Participants are randomly assigned to receive…

This phase 2 trial tests a combination of two drugs—becotatugvedotin (a targeted therapy that delivers a toxin directly to cancer cells) and pucotenlimab (an immunotherapy that helps the immune system attack cancer)—as a second-line treatment for people with advanced gastric or g…

This trial tests a follow-up strategy for people with nasopharyngeal cancer that has spread to neck lymph nodes (N3) after radiation therapy. Participants are assigned to standard follow-up or an enhanced approach that uses advanced imaging and a blood test (EBV DNA) to decide if…

This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan (Sac-TMT) and fruquintinib—as a second-line treatment for people with advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after initial therapy. The study enrolls about 45 par…

This phase 2 trial tests the drug velzatinib in people with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to or cannot tolerate several standard treatments. The study aims to see if velzatinib can shrink or control the tumors and how safe it is. Par…

This phase III trial is testing whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy after short-course radiation can improve outcomes for people with a specific type of locally advanced rectal cancer (pMMR/MSS). Participants receive eith…

This trial tests a new drug called DN022150 in people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. Participants have already received at least one prior treatment. The study compares DN022150 alone against standard chemotherapy options to s…

This early-phase trial tests whether adding mild heat therapy (thermotherapy) to standard chemoradiation is safe and tolerable for people with advanced head and neck cancer. The heat, applied once a week, aims to make the cancer more sensitive to treatment. The study includes two…

This trial investigates whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, can control advanced liver cancer in patients with moderate cirrhosis (Child-Pugh B). The dosing is adjusted based on how each patient responds. The study aims to see how many pati…

This pilot study explores whether patients with margin-clear stage II or III rectal cancer who do not need a permanent colostomy can safely go straight to surgery instead of receiving chemotherapy first. Participants are randomly assigned to either 12 weeks of chemotherapy follow…

This clinical trial is testing a combination of two experimental drugs, IMM2510 and IMM27M, in people with advanced hepatocellular carcinoma (a type of liver cancer) who have not yet received treatment for their advanced disease. The drugs are designed to help the immune system r…

This study investigates whether regular blood tests can detect liver cancer earlier in people with type 2 diabetes who also have significant liver scarring. Participants are randomly assigned to either a surveillance group receiving specialized blood tests every six months or a s…

This study tests a new approach for people with locally advanced stomach cancer that has not spread to other organs. First, patients receive heated chemotherapy directly into the abdomen to kill any hidden cancer cells. Then they get an immunotherapy drug (serplulimab) combined w…

This pilot study tests a new device that uses radiofrequency energy to seal the pancreas during robotic surgery to remove the tail of the pancreas. The device, called Attachable Coolingbis®, is designed to reduce the common complication of pancreatic fluid leaks. Twenty adults wi…

This phase 2 trial tests a single drug called PD-1/IL-2α-bias bispecific antibody fusion protein in people with advanced or metastatic esophageal squamous cell carcinoma whose cancer worsened after prior immunotherapy and chemotherapy. The drug is designed to boost the immune sys…

This study tests an experimental drug, TAX2, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in more people. Researchers will monitor side effects, h…

This trial investigates whether adding two targeted drugs—tafolecimab and sintilimab—to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer that has not spread. Participants receive short-course radiation followed by chemotherapy plus immun…

This phase 2 trial tests a new treatment approach for people with locally advanced pancreatic cancer that cannot be removed by surgery. Participants receive targeted radiation therapy followed by a combination of two immunotherapy drugs (ipilimumab N01 and sintilimab) plus standa…

This phase 2 trial tests the drug zanzalintinib in people whose adenoid cystic carcinoma (a rare salivary gland cancer) has returned or spread. Despite initial surgery and radiation, about half of patients experience recurrence, and current treatments offer limited benefit. Parti…

This trial investigates whether adding the drug savolitinib to standard chemotherapy plus cetuximab improves tumor shrinkage in people with a specific genetic subtype (RAS/BRAF wild-type) of metastatic colorectal cancer that has not been treated before. Participants are randomly …

This phase II trial tests a combination of two drugs—SYS6026 and Enlonstobart—in people with advanced solid tumors that have spread and are linked to HPV types 16 or 18. The study aims to see if the combination is safe and shows signs of shrinking tumors. Participants must be at …

This study tests a new drug called becotatugvedotin combined with the chemotherapy gemcitabine for people with advanced pancreatic cancer that has not responded to first-line treatment. The trial has two phases: first, to find the safest dose of the new drug, and second, to see h…

This trial investigates whether adding the targeted antibody zanidatamab to standard chemotherapy can shrink HER2-positive stomach or gastroesophageal junction cancers before surgery. It includes two groups: people with locally advanced cancer that has not spread, and those with …

This study tests whether giving a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted drug (rivoceranib) before surgery can improve outcomes for people with liver cancer that can be surgically removed. Participants receive the drug combination first, then und…

This trial compares two techniques—snare tip soft coagulation and hybrid APC—used to burn the edges of the wound after removing large colon polyps. The goal is to see which method is faster while still preventing polyps from coming back. About 140 adults with large non-cancerous …

This study tests whether two common heart medications—atorvastatin (a statin) and lisinopril (an ACE inhibitor)—can prevent or reduce heart damage caused by radiation therapy for chest cancers like breast, lung, and esophageal cancer. About 60 adults receiving chest radiation wil…

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This phase II trial is testing whether a combination of treatments can help people with a type of liver cancer that cannot be removed by surgery. The approach uses local chemotherapy delivered directly to the liver, along with immunotherapy (toripalimab) and a targeted therapy pi…

This phase 2 trial tests whether the combination of pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy) can shrink tumors in people with advanced anal squamous cell cancer that cannot be removed by surgery or has spread to other organs. Participants must have alr…

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This study tests a new biologic drug called HCB101 in combination with other cancer drugs (zolbetuximab and chemotherapy) for people with advanced gastric or gastro-esophageal cancer. The goal is to find a safe dose and see if the combination can shrink tumors. About 40 adults wi…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This phase II trial investigates whether adding SHR-8068 to a two-drug regimen (adebrelimab and apatinib) can improve outcomes for people with liver cancer that can be surgically removed but has a moderate-to-high risk of coming back. Participants receive the drug combination bef…

This study tests whether a personalized nursing program can prevent acute kidney injury (AKI) in people with liver cancer who undergo interventional therapy. Researchers first use a prediction model to classify patients into low, moderate, or high risk for AKI. Then, they provide…

This large Phase 3 trial is testing a new drug called APG-157, given as a pastille that dissolves in the mouth, for people with advanced head and neck cancer. The study will see if adding APG-157 before and after standard treatments (surgery or chemoradiation) helps keep the canc…

This study tests whether a short course of radiation followed by the immunotherapy drug tislelizumab plus chemotherapy can improve outcomes for people with a type of esophageal cancer that can be surgically removed. About 50 participants will receive either a low or high dose of …

This phase 2 trial is testing whether giving two drugs—Zanzalintinib and Retifanlimab—before surgery can help patients with early-stage colon cancer. The study enrolls adults aged 18 to 80 with a type of colon cancer called pMMR that can be removed surgically. Participants receiv…

This phase 3 trial tests whether adding the experimental drug SHR-A1811 to standard chemotherapy and bevacizumab works better than standard therapy alone for people with advanced colorectal cancer who have not had prior treatment. About 300 participants will receive either the ne…

This phase 3 trial compares a new drug called Retlirafusp alfa plus chemotherapy against standard immunotherapy plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread to the liver and has not been treated before. The study aims to s…

This study investigates whether adding a short course of radiotherapy before surgery, alongside a PD-1 inhibitor (serplulimab) and chemotherapy (SOX), can improve outcomes for people with locally advanced upper stomach or gastroesophageal junction cancer. Participants are randoml…

This study tests a combination of targeted radiation (SBRT) and an experimental drug called QL1706 in 36 adults with advanced liver cancer that has worsened after one prior treatment. The radiation is given to liver tumors over five sessions, followed by QL1706 infusions every th…

This phase 2 trial tests whether adding an experimental drug called tovecimig to standard chemotherapy (FOLFIRI) can shrink tumors or slow cancer growth in people with metastatic colorectal cancer who have already tried one prior treatment. The study will enroll 25 participants a…

This phase 2 trial tests whether combining sintilimab (an immunotherapy) with gossypol acetate (a compound from cottonseed) can shrink tumors in people with advanced colorectal cancer that has not responded to at least two prior treatments. The study will enroll 32 adults aged 18…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This phase 2 trial tests whether adding a new form of interferon (rSIFN-co) to standard total neoadjuvant therapy (short-course radiation plus chemotherapy) can improve the chance of complete tumor disappearance in people with mid-low locally advanced rectal cancer. About 90 adul…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This study tests a new drug called samuraciclib added to standard chemotherapy for people with a specific type of advanced pancreatic cancer (basal-like). The goal is to find the safest dose and see if the combination helps shrink tumors or slow the cancer. About 67 adults with n…

This phase 2 trial tests a combination of three drugs—sintilimab, ramucirumab, and paclitaxel—in 30 adults with HER2-negative stomach cancer that came back during or within 6 months of finishing adjuvant therapy. The main goal is to see how many patients' tumors shrink significan…

This study tests a radiation treatment called SIRT (selective internal radiation therapy) using tiny radioactive beads delivered directly to liver tumors. The goal is to shrink tumors enough so that patients with liver cancer can qualify for a liver transplant or have surgery to …

This phase 1 trial tests a radioactive drug called 211At-MABG in 16 adults with advanced neuroendocrine cancers, including pheochromocytoma and paraganglioma. The drug delivers radiation directly to cancer cells that show up on a special scan. The main goal is to see if the treat…

This phase 2 trial tests whether adding the targeted drug fruquintinib to standard immunotherapy (sintilimab) and chemotherapy (SOX) can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 120 participants will receive either the t…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This study tests whether matching drug combinations to a patient's tumor genetics can help when standard immunotherapy stops working. About 90 people with advanced esophageal cancer will get one of three treatment pairs based on their cancer's molecular profile. The goal is to se…

This study looks at whether immunotherapy can shrink certain gastrointestinal cancers (like colorectal or stomach cancer) enough that some patients may not need major surgery. People whose tumors have specific genetic features (MSI-H/dMMR or POLE mutation) and who respond well to…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This early-stage trial tests a drug called ACM-CpG, which is injected directly into the abdomen to stimulate the immune system against cancer. It includes 24 adults with colorectal or appendix cancer that has spread to the lining of the abdomen or caused fluid buildup. The main g…

This phase 2 trial tests a combination of four drugs—mannatide, two chemotherapy drugs, and an immunotherapy—as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has spread or come back. The study will enroll 52 participants to see if the…

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…

This study tests a new drug called DN022150 combined with standard chemotherapy (AG) as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. About 465 adults aged 18-75 who have not had prior treatment for advanced disease will tak…

This early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…

This study tests a treatment called NRT6003, which delivers tiny radioactive beads directly to liver tumors through a blood vessel. It is for people with liver cancer that has already been treated but not cured. The goal is to see if this single session of internal radiation can …

This study tests a new drug called TQB2930, which targets the HER2 protein on cancer cells, combined with standard chemotherapy and possibly another drug (bevacizumab). The goal is to find the safest and most effective dose and see if it shrinks tumors in people with advanced col…

This early-phase trial tests a new drug called nelmastobart, combined with two existing cancer drugs (TAS-102 and bevacizumab), in 45 Chinese patients with advanced colorectal cancer that has not responded to standard treatments. The main goal is to check safety and how the body …

This study tests a combination of the immunotherapy drug sintilimab and a chemotherapy regimen called FOLFIRI as a second-line treatment for people with advanced HER2-negative stomach cancer that has progressed after initial therapy. The goal is to see if this approach can delay …

This phase II trial tests a new approach for high-risk locally advanced rectal cancer. Participants first receive short-course radiotherapy, followed by a combination of chemotherapy (NALIRIFOX) and immunotherapy (Pucotenlimab) for about 6 months. The goal is to see if this regim…

This trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), can be grown in a lab and then given back to fight advanced gastrointestinal stromal tumors (GIST). The study includes people whose GIST has spread, come back, or cannot be remove…

This study tests a procedure called calcium electroporation to stop bleeding from stomach cancer tumors. Doctors inject calcium into the tumor and use a special device to deliver small electrical pulses, which can help control bleeding. The trial will include 28 patients with adv…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This early-stage trial tests a new drug called EMB-01, a bispecific antibody that targets two cancer-related proteins, combined with standard chemotherapy. About 120 adults with advanced colorectal cancer that cannot be surgically removed will receive the combination. The main go…

This phase II trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—in 30 adults with advanced biliary tract cancer whose first treatment stopped working. The goal is to see if the combo can shrink tumors and improve sur…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This study tests whether adding an experimental immunotherapy drug (QL1706) to standard chemotherapy and radiation can shrink liver tumors from colon cancer enough to allow surgery. About 30 adults with colon cancer that has spread only to the liver will receive the combination b…

This small study tests a new approach for people with stage II/III rectal cancer that has not spread. Instead of chemotherapy, patients receive targeted internal radiation followed by two doses of the immunotherapy drug nivolumab before surgery. The goal is to see if this combina…

This study tests an experimental drug (PD-1/IL-2 bispecific antibody) given before a second surgery in 30 adults whose liver cancer returned early after initial curative surgery. The goal is to see if the drug can shrink or kill more cancer cells before the operation, potentially…

This study looks at whether people with certain genetic types of gastrointestinal cancers (stomach, colorectal, or anal) can safely avoid major surgery after immunotherapy. Instead of removing the organ, doctors will monitor closely or do smaller procedures to remove any remainin…

This phase 2 trial tests whether combining two immunotherapy drugs (ipilimumab and sintilimab) with chemotherapy (modified XELOX) can shrink locally advanced stomach cancer that cannot be surgically removed. The goal is to make the tumors small enough for surgery. The study enrol…

This early-stage trial tests whether combining two drugs—selumetinib and DS-8201a—can safely shrink or control advanced pancreatic cancer that has a specific genetic change (KRAS mutation) and a protein called HER2. About 31 adults with cancer that cannot be removed by surgery or…

This early-phase trial tests a new peptide nanovaccine (ONVAX-01) together with an anti-PD-1 antibody and standard chemotherapy in 9 people with advanced pancreatic cancer that has worsened after prior treatment. The main goals are to see if the combination is safe and whether it…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This phase II trial tests whether giving a mix of immunotherapy (durvalumab), chemotherapy (cisplatin and gemcitabine), and possibly a targeted drug (futibatinib) before surgery can improve outcomes for patients with resectable intrahepatic cholangiocarcinoma, a type of bile duct…

This phase II trial tests whether a genetic signature can personalize chemotherapy for people with borderline resectable pancreatic cancer. About 110 participants will receive either a standard chemo regimen or one chosen based on their tumor's genetic profile. The goal is to see…

This phase 2 trial tests a new drug called AUR103 calcium in 30 people with advanced neuroendocrine tumors that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug twice daily unt…

This study tests a new drug called JAB-23E73, which targets KRAS gene changes, combined with two standard chemotherapies (nab-paclitaxel and gemcitabine) in people whose pancreatic cancer has spread and who haven't had prior treatment. The goal is to see if the combination is saf…

This study looks at whether a combination of two immunotherapy drugs (Durvalumab and Tremelimumab) can control advanced stomach cancers with specific genetic features (dMMR/MSI-H) well enough to avoid surgery. The trial enrolls 12 adults who would normally need chemotherapy and s…

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can help people with advanced bile duct cancer live longer without their cancer growing. About 123 adults with untreated, inoperable bile duct cancer will be randomly assigned to …

This early-phase trial tests a combination of three drugs—TAS-102, bevacizumab, and serplulimab—in 20 people with metastatic colorectal cancer who have already had surgery to remove tumors. The goal is to see if the combination is safe and can delay cancer progression. Participan…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This early-phase trial tests a new drug called AB801, which blocks a protein (AXL) that helps cancers grow and resist treatment. It is given alongside chemotherapy and immunotherapy to people with bile duct or pancreatic cancer that is either borderline resectable, locally advanc…

This study tests a new treatment plan for people with HPV-positive oropharyngeal cancer (a type of throat cancer linked to HPV). The plan combines an immune-boosting drug (nogapendekin alfa inbakicept), a vaccine targeting HPV, chemotherapy, and a lower dose of radiation. The goa…

This phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—as a first treatment for advanced head and neck squamous cell carcinoma. It is for patients whose cancer has returned or spread and who cannot tolerate p…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This study tests a new chemotherapy regimen called FOLFOX8 against the standard mFOLFOX6, both combined with targeted drugs (bevacizumab or cetuximab), as a first treatment for people with metastatic colorectal cancer that cannot be surgically removed. About 229 participants will…

This study tests a combination of two immunotherapy drugs (iparomlimab and toripalimab) plus bevacizumab and chemotherapy as a first treatment for advanced biliary tract cancer. It involves 32 adults aged 18-75 who have not had prior treatment for their advanced cancer. The goal …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests whether injecting a special solution (KRC-01) into rectal tumors before radiation can make the radiation work better. The solution increases oxygen inside the tumor, which helps radiation kill cancer cells. About 24 adults with advanced rectal cancer that hasn't …

This Phase 3 trial tests a new drug called HS-20093 against standard chemotherapy in 494 people with advanced esophageal cancer that has worsened after initial treatment. The goal is to see if HS-20093 helps people live longer and controls the tumor better. Participants will rece…

This study tests whether adding a new drug called retlirafusp alfa to standard chemotherapy before surgery can help shrink tumors in people with a type of esophageal cancer. About 33 adults with locally advanced esophageal squamous cell carcinoma will receive the combination trea…

This early study tests if a new, needle-based treatment using brief electric pulses can safely destroy certain pancreatic tumors without surgery. The treatment aims to spare healthy tissue nearby. About 12 adults with specific pancreatic cysts or low-grade tumors will be enrolled…

This phase 2 trial is testing whether adding an immunotherapy drug (adebrelimab) to a chemotherapy combo (NALIRIFOX) and radiation can improve outcomes for people with a certain type of locally advanced rectal cancer (pMMR/MSS). About 84 participants will be randomly assigned to …

This study tests a new drug called HDM2017 combined with standard treatment (fruquintinib) in 120 people with advanced colorectal cancer that has spread. The goal is to find the safest dose and see if the combination can shrink tumors. Participants must have tried other treatment…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests whether giving a combination of chemotherapy directly into the liver (HAIC) plus two drugs (camrelizumab and apatinib) before and after surgery can prevent liver cancer from returning in high-risk patients. About 208 people with resectable liver cancer and high-r…

This phase 2 trial is testing a combination of two targeted drugs (fruquintinib and serplulimab) plus chemotherapy as a first treatment for 80 people with advanced colorectal cancer that has RAS or BRAF mutations. The goal is to see if this mix can delay cancer growth and improve…

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This phase 2 trial tests whether adding a cholesterol-lowering drug (Tafolecimab) to standard immunotherapy (Sintilimab) and chemotherapy (SOX) can shrink tumors in 30 people with advanced pMMR/MSS gastric cancer, a type that usually doesn't respond well to immunotherapy alone. T…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This study tests whether adding sodium propionate, a common food preservative, to standard immunotherapy and chemotherapy can improve tumor shrinkage in people with advanced stomach cancer. About 20 adults with inoperable gastric cancer will be randomly assigned to receive either…

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This early-phase trial is testing a new mRNA-based drug called YMN-A02 in 10 people with advanced colorectal cancer that has spread to the liver and has not responded to standard treatments. The drug is designed to help the immune system attack the cancer by producing a CTLA-4 an…

This phase 2 trial tests a combination of three drugs—retlirafusp alfa, apatinib, and nab-paclitaxel—in 50 adults with advanced stomach or gastroesophageal junction cancer that has progressed after first-line immunotherapy. The goal is to see if the combination can shrink tumors …

This study tests a new way to deliver radiation for gastric MALT lymphoma. Using AI, the treatment adapts each session to better protect nearby organs. About 25 adults with early-stage disease will take part. The goal is to see if this approach is safe and effective.

This study tests a new drug combination (SKB315 plus an immunotherapy) in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 80 participants in China will receive the treatment to see if it shrinks tumors. The goal is to cont…

This phase II trial tests whether a stronger chemotherapy cocktail (cmFOLFOXIRI) plus an immunotherapy drug (PD-1 inhibitor) works better than standard chemotherapy (mFOLFOX6) when given before surgery for locally advanced colon cancer. About 138 patients with high-risk stage II …

This phase 3 study tests whether a new drug called Enlituo, combined with chemotherapy (FOLFOX), works as well as the standard treatment Erbitux plus FOLFOX for people with advanced colorectal cancer that has specific genetic traits (RAS/BRAF wild-type and MSS/pMMR). About 608 ad…

This early-phase trial is testing a combination of two drugs—trastuzumab rezetecan and retlirafusp alfa—in 12 people with HER2-positive stomach or gastroesophageal junction cancer. The treatment is given before surgery to see if it can safely shrink tumors. The main focus is on s…

This early-stage trial tests a personalized cancer vaccine called ODI-2001 in 77 people with advanced colon or pancreatic cancer that has spread or cannot be removed. The vaccine is custom-made for each patient's tumor and is given along with a drug that boosts the immune system.…

This trial asks whether adding artificial intelligence (AI) to radiologists' reading of liver CT scans can match or improve standard reporting. It involves 40,000 adults who had contrast-enhanced CT scans of the abdomen. On some days, radiologists first read scans on their own, t…

This trial investigates whether a special PET imaging tracer called [18F]FTT can help predict how well people with newly diagnosed bile duct cancer (cholangiocarcinoma) will respond to standard chemotherapy. The tracer binds to a protein called PARP1, which some tumor cells produ…

This study looks at whether a special ultrasound technique called detective flow imaging (DFI) can help doctors tell the difference between benign and malignant solid pancreatic lesions. Researchers will examine the blood vessel patterns seen with this technique and compare them …

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This study investigates whether tiny particles shed by tumors into the blood, called extracellular vesicles, can serve as a non-invasive biomarker for metastatic colorectal cancer. Researchers will analyze blood samples from 290 patients at different treatment stages to see if th…

This study tests whether annual liquid biopsies (from blood, urine, stool, and vaginal swabs) can safely replace colonoscopies every 18 months for people with Lynch syndrome. 2,000 participants will be split into two groups: one gets standard care (colonoscopy every 18 months), t…

This study will test an artificial intelligence system that screens for breast, liver, kidney, and bladder cancers using standard CT scans taken for other reasons. Researchers plan to enroll 100,000 participants to see if the AI can catch tumors earlier and help doctors reduce mi…

This trial tests whether an AI system called GI Genius can help doctors accurately tell apart small colorectal polyps (5 mm or less) during a colonoscopy—identifying which ones are harmless versus those that need monitoring. For each small polyp, doctors first record their own di…

This trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…

This trial explores whether betacyanin, a pigment found in beetroot, can help doctors detect anastomotic leakage — a serious complication where intestinal contents leak after rectal cancer surgery — earlier than current methods. About 120 people undergoing laparoscopic rectal can…

This trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…

This pilot study tests whether a structured case-finding pathway can help detect pancreatic cancer earlier in Swiss primary care. Adults aged 60 or older with warning signs like new-onset diabetes, unexplained weight loss, or a family history of pancreatic cancer are invited to u…

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This study compares two imaging methods for checking blood flow to the bowel during colorectal surgery: the standard technique using a dye called indocyanine green (ICG) and a newer dye-free method called Laser Speckle Contrast Imaging (LSCI). About 30 adults having elective colo…

This study tests a new ultrasound method called super-resolution ultrasound (SRUS) to see tiny blood vessels in liver tumors. Current scans show only larger vessels, but SRUS can detect vessels as small as 20 micrometers. Researchers will compare blood flow patterns in different …

This study aims to find molecular clues that could predict whether certain pancreatic growths will turn into cancer. Researchers will analyze tissue from patients having pancreatic surgery, using advanced genetic and protein tests on both the original tissue and lab-grown 3D cell…

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This study investigates whether a new ultrasound technology called Superb Microvascular Imaging (SMI) can accurately analyze material inside pancreatic cysts (PIMPTs) without using a contrast agent. Currently, doctors inject a contrast dye during endoscopic ultrasound to assess c…

This early-phase study will test two radioactive tracers designed to light up certain solid tumors on scans. Twenty adults with breast, head and neck, pancreatic cancer, or glioma will receive an injection of the tracers and then undergo PET/CT and SPECT/CT imaging. The goal is t…

This study tests whether a fluorescent tracer called WGA-800CW can make precancerous or cancerous cells in Barrett's esophagus glow during endoscopy. The tracer is sprayed onto the esophagus, and special cameras detect the glow. The goal is to find the best dose and see if this m…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study compares two devices (EYEMAX and SPYGLASS) used to take tissue samples from the bile duct to diagnose cancer. About 120 adults with bile duct narrowing will be randomly assigned to one device. The goal is to see which tool gives more accurate cancer diagnoses.

This study tests a new, non-invasive method to detect colorectal cancer and precancerous growths by analyzing odors from breath and intestinal gas. About 453 participants—including people with colorectal cancer, precancerous lesions, and healthy volunteers—will provide samples an…

This early-phase trial tests a new radioactive tracer (64Cu-DOTA-A2DM) for PET scans in people with advanced pancreatic cancer that has spread. The tracer is designed to attach to a protein called PSCA found on some pancreatic cancer cells, making them visible on the scan. The st…

This study tests whether spraying a mix of acetic acid and indigo carmine dye during colonoscopy helps doctors find more precancerous polyps (called sessile serrated lesions) in the right side of the colon compared to standard white-light colonoscopy. About 2,689 adults aged 45-8…

This pilot trial tests a community-based program designed to help Chinese immigrants aged 45-75 get up-to-date on colorectal and breast cancer screening. The program includes a group education session led by a community health worker and personalized help navigating the healthcar…

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This Phase 2 trial tests whether psilocybin, a psychedelic compound, can prevent or lessen chemotherapy-induced peripheral neuropathy (nerve damage) in people with breast, colorectal, or head and neck cancer. About 83 participants will receive either psilocybin, a low-dose placeb…

This early-stage trial tests whether a daily supplement called SAMe can help prevent colorectal polyps (precursors to colon cancer) in 18 adults who have already had surgery for early-stage colon cancer. Participants will take SAMe for up to a year while researchers monitor for s…

This study tests whether a multilevel screening program can increase colorectal cancer screening rates among Veterans aged 45-49, an age group now recommended for screening due to rising early-onset cases. Participants are randomly assigned to receive a patient education letter a…

This study tests whether a one-day health awareness campaign in community pharmacies can encourage more Malaysian adults aged 50 to 75 to get screened for colorectal cancer. Participants receive educational materials and one-on-one guidance about the disease and a simple home scr…

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …

This study tests whether electroacupuncture (using mild electric pulses on needles) plus tiny thumbtack needles can prevent nerve damage caused by chemotherapy in people with early-stage cancer. About 278 patients with breast, stomach, bowel, lung, or ovarian cancer will receive …

This study tests whether electroacupuncture (acupuncture with mild electrical pulses) combined with tiny thumbtack needles can prevent peripheral neuropathy—numbness, tingling, or pain—caused by chemotherapy in people with advanced cancer. The trial enrolls adults with stage IV b…

This study tests whether an AI-powered chatbot and smart reminders can encourage more high-risk adults aged 45 to 74 to get a colonoscopy, the best way to detect colorectal cancer early. About 1,680 participants will be split into two groups: one gets usual care, the other also g…

This pilot study tests two light therapy devices—one placed inside the mouth and one outside—to prevent and treat painful mouth sores caused by radiation therapy. Sixty adults with oral cavity or oropharynx cancer will receive light sessions twice a week for prevention, then thre…

This phase III trial tests whether a vaccine made from a person's own immune cells can prevent cancer in 372 adults with Lynch syndrome, a genetic condition that raises cancer risk. Participants receive either the vaccine or a placebo and are monitored for tumor development. The …

This early-phase trial tests whether a device that blocks signals from the vagus nerve can safely help patients with metastatic pancreatic cancer who are experiencing severe weight loss (cachexia). The device is placed on the skin over the nerve and is used alongside chemotherapy…

This study is for people with HPV-related oropharyngeal (throat) cancer, which often responds well to treatment. The goal is to see if lowering the radiation dose to certain areas can reduce side effects like dry mouth without hurting the chance of curing the cancer. About 132 pa…

This pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…

This trial tests whether a home-based, digitally supervised prehabilitation program—using 5G and AI—can help gastric cancer patients get fitter before surgery. Participants who have completed chemotherapy and are scheduled for stomach removal will either receive standard care or …

This study tests whether an AI-powered program can help older adults with serious illnesses like cancer or heart disease manage emotional distress. Participants receive short videos and daily check-ins from a chatbot that teaches practical coping skills, all from their own phone.…

This study explores whether a personalized music therapy session, called music-assisted relaxation and imagery (MARI), can reduce pain and change gene activity in people recovering from open surgery for stomach, pancreas, bile duct, liver, or peritoneal cancer. Participants will …

This study tests a digital tool called RECapp that helps patients recover after surgery for esophageal or stomach cancer. The app lets patients track symptoms, get personalized self-care advice, and know when to contact their healthcare team. 250 adults in Sweden will use the app…

This trial tests whether mind-body practices like breathwork, meditation, and gentle yoga can improve quality of life, stress, and sleep in people who have recently finished cancer treatment. Participants will practice these techniques weekly for six weeks while wearing an activi…

This trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…

This pilot study tests whether delivering pain medication directly to the spinal cord via an implanted pump can better control severe pain in people with pancreatic cancer. The trial enrolls adults whose pain is not well managed by standard treatments or who cannot take typical p…

This trial tests whether remimazolam, an anesthetic drug, can improve sleep quality in older adults after laparoscopic colorectal cancer surgery, compared with the standard anesthetic propofol. Participants aged 65-80 will be randomly assigned to receive one of the two anesthetic…

This phase III trial tests whether a daily probiotic supplement, OXXYSLAB®, can reduce peripheral neuropathy—nerve damage causing pain and numbness—in people with stage III colon cancer receiving oxaliplatin-based chemotherapy (FOLFOX or XELOX). About 130 participants will take e…

This study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…

This trial tests whether a nurse-led program combining an AI chatbot and home-based exercises can help advanced gastric cancer patients on immunotherapy feel less frail and have a better quality of life. Participants use the chatbot to report side effects and get personalized adv…

This phase II trial investigates whether a specially formulated yogurt rich in butyrate—a short-chain fatty acid—can relieve constipation in people with gastrointestinal cancer. Constipation is a common and distressing side effect of cancer and its treatments, and current medicat…

This study tests whether transcutaneous electrical acupoint stimulation (TEAS) — a needle-free treatment that sends mild electrical pulses through sticky pads on the skin — can help people recover faster after laparoscopic surgery for stomach cancer. Researchers are comparing thr…

This study tests whether a mobile-based rehabilitation program, built on the PERMA-H model of well-being, can improve hope, self-confidence, and social support in people recovering from a tracheostomy due to oral cancer. Participants use a WeChat mini-program with a chatbot and t…

This trial investigates whether gentle abdominal massage, performed early after colon cancer surgery, can help the intestines start working again more quickly. Many patients experience a temporary slowdown in gut function (postoperative ileus) that causes bloating, pain, and naus…

This study investigates whether a traditional Chinese mind-body practice called Baduanjin Qigong, combined with standard exercises, can improve muscle strength and quality of life in adults aged 35–55 with colorectal cancer who are undergoing chemotherapy. Participants will take …

This study looks at whether starting trans-anal irrigation (a procedure that uses warm water to help empty the bowel) within three months of stoma closure reduces daily bowel movements more than starting later. The trial involves 250 adults who have had rectal cancer surgery and …

This trial tests whether a short course of precisely targeted radiotherapy can safely reduce severe pain in people with advanced pancreatic cancer. The radiation is aimed at the coeliac plexus, a network of nerves in the abdomen that often causes pain when affected by the tumor. …

This trial compares a fixed-dose combination of acetaminophen and ibuprofen (Maxigesic) against acetaminophen alone for pain relief after minimally invasive stomach cancer surgery. 160 adults scheduled for radical gastrectomy will receive either the combo or standard acetaminophe…

This study tests whether adding electroacupuncture at specific acupoints (Xuanzhong and Tongli) to standard speech therapy improves language recovery in people with post-stroke aphasia. Participants receive daily electroacupuncture sessions for four weeks, plus speech therapy. Th…

This trial compares early versus delayed acupuncture to reduce dry mouth caused by chemoradiation in head and neck cancer patients. Participants receive acupuncture either during chemoradiation or after, and their dry mouth symptoms are tracked for a year. The goal is to find the…

This study tests whether an AI-based website that gives personalized diet tips and recipes can help cancer patients who experience taste changes during therapy. About 198 adults with certain cancers (like multiple myeloma, melanoma, or GI cancers) will either get the AI tool or a…

This study tests whether taking high doses of vitamin E and CoQ10 daily for 90 days can reduce chronic side effects from pelvic radiation in people treated for prostate, uterine, cervical, or anal cancer. Researchers will monitor safety, side effects, and quality of life in 200 a…

This study tests a mobile app called GutCheck for people who have survived gastrointestinal cancer. Participants track their diet, stress, and gut symptoms daily. The app analyzes the data to identify potential trigger foods. The goal is to see if the app is feasible and helpful …

This study tests whether an artificial intelligence-based dietary care app can reduce distress from bowel changes and improve quality of life in rectal cancer patients who have had anal-preserving surgery. One hundred participants will be randomly assigned to either standard diet…

This study looks at whether a prehabilitation program—including physical therapy, dietary advice, and emotional support—given before major cancer surgery can reduce deaths and serious complications within 30 days after the operation. About 180 adults with cancers of the pancreas,…

This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study tests a 6-week health behavior program for 40 colorectal cancer patients who are at least 3 months past surgery. The program uses counseling and support to encourage healthy habits like diet and exercise. Researchers want to see if it's practical and helps improve pati…

This early study tests an augmented reality (AR) system that overlays a tumor's image onto the liver during keyhole surgery. Six adults scheduled for liver tumor removal will participate. The goal is to see if the AR guidance helps surgeons remove tumors more completely and safel…

This study tests whether a 12-week exercise program, delivered via Zoom, is practical and helpful for older adults (65+) with cancer who live in rural areas. Participants will do two supervised exercise sessions per week. The goal is to see if the program improves quality of life…

This study tests whether combining two ultrasound-guided nerve blocks (transversus abdominis plane block and rectus sheath block) can better control pain and speed recovery after robotic colon cancer surgery. About 90 adults having their first robotic colectomy will receive the b…

This observational study looks at how pancreatic cancer changes immune cells in the blood. Researchers will compare blood samples from 50 people with newly diagnosed, untreated pancreatic cancer to 50 age-matched people with a non-cancerous pancreatic condition. They aim to ident…

This study looks at whether a structured surveillance program using regular ultrasound and a blood test (alpha-fetoprotein) can detect liver cancer at an earlier, more treatable stage in people at high risk. About 300 adults with liver cirrhosis, chronic hepatitis B, or advanced …

This early-stage study tests whether a magnetic tracer and a fluorescent dye can safely help doctors find lymph nodes where stomach cancer may have spread. About 20 adults with early stomach cancer will receive the injection before surgery. The goal is to see if this method is sa…

This study tests a program called HOLA that teaches oncologists special communication skills to build better relationships with their Latino patients who have advanced cancer. Researchers will compare how strong the bond is between doctors who take the training and those who don'…

This study will follow 110 adults in Poland with metastatic colorectal cancer (cancer that has spread) who are taking fruquintinib after at least two prior treatments. Researchers will track how long patients live without their cancer getting worse and their overall survival, usi…

This observational study is investigating whether certain blood markers and gut microorganisms can help identify people with chronic pancreatitis who are at higher risk of developing pancreatic cancer. Researchers will compare healthy individuals, those with chronic pancreatitis,…

This study looks at people who had surgery for advanced lower rectal cancer, comparing two procedures: one that removes the rectum and anus (requiring a permanent stoma) and one that removes the rectum but keeps the anus (with a reconnection). The goal is to see which approach le…

This study tests whether adding a technique called vascular deformation mapping (VDM) to standard CT scans can better predict liver failure after major liver surgery. Researchers will analyze routine preoperative CT images from over 1,000 adults undergoing removal of at least thr…

This study looks at whether a combination of immune cell activity, genetic changes, and imaging features can help predict if colorectal cancer that has spread to the liver will come back after surgery. Researchers will analyze tumor tissue, blood samples, and scans from about 210…

This study asks whether an artificial intelligence system can make the same care recommendations as a team of cancer experts for people with stomach, colon, or rectal cancer. About 69 participants will have their medical information reviewed independently by both the AI and a mul…

This phase 2 trial tests whether a highly sensitive blood test (ctDNA) can help manage treatment for 200 people with early-stage rectal cancer. After standard chemotherapy and radiation, some patients will have their treatment guided by the blood test results instead of immediate…

This study aims to find biological markers in saliva, mouth rinse, blood, or tissue that could help identify and predict the course of oral cancer, gum disease, and tooth decay. Researchers will collect health information and samples from 4,000 adults with these conditions and he…

This study looks at whether a new blood test can find tiny bits of tumor DNA left behind after pancreatic cancer surgery. About 30 adults who had their cancer removed will give blood samples at three key times over six months. The goal is to see if this test can detect remaining …

This study is looking at whether a person's traditional Chinese medicine (TCM) constitution—a concept that categorizes individuals into different body types—can help predict who will experience diarrhea as a side effect of combined immunotherapy and targeted therapy for liver can…

This study investigates whether substances in the blood can predict how patients with advanced liver cancer respond to a combination of atezolizumab and bevacizumab. Researchers will analyze leftover blood samples from routine tests in 100 patients to look for patterns linked to …

This study tests whether a specialized MRI technique, called hyperpolarized 13C-MRI, can detect early metabolic changes in gastrointestinal stromal tumors (GIST) during treatment with imatinib. Standard scans like CT and MRI only measure tumor size, which can take months to chang…

This study aims to develop a diagnostic model that predicts the risk of colorectal cancer and advanced polyps in adults aged 18 to 80 who are already scheduled for a routine colonoscopy in China. Participants fill out a questionnaire about their lifestyle, medical history, and sy…

This study collects and organizes data from 3,000 real pancreatic cancer patients, including those with early, advanced, and inoperable disease. Medical experts will label and structure the information to create a high-quality knowledge base. The goal is to train artificial intel…

This study investigates whether a specialized MRI scan called three-dimensional magnetic resonance elastography (3D-MRE) can predict how well patients with initially unresectable liver cancer will respond to conversion therapy. The scan measures the stiffness and other physical p…

This study looks at 3,000 people who had surgery for colorectal cancer to see how often polyps come back in the colon afterward. Researchers will check if the type and stage of the original cancer are linked to polyp recurrence. The goal is to improve follow-up care by identifyin…

This study investigates whether a special 3D MRI scan, called magnetic resonance elastography (3D-MRE), can detect microscopic tumor remnants at the surgical margin after liver cancer removal. Current methods only examine the removed tissue, not the remaining liver. Researchers w…

This trial investigates whether a special type of MRI scan, called DCE-MRI, can better assess how well chemotherapy is working in people with borderline resectable pancreatic cancer. Participants will receive standard chemotherapy and undergo DCE-MRI scans along with regular imag…

This study explores whether a special 3D MRI scan, called magnetic resonance elastography, can measure liver stiffness and elasticity before surgery to predict the risk of liver failure afterward. Researchers will enroll 150 adults with liver cancer or liver metastases who are sc…

This study investigates whether two blood-based biomarkers—circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP)—can predict how well colon cancer responds to pre-surgery therapy. About 80 adults with stage III colon cancer will provide extra blood samples before, duri…

This study follows 400 people with esophageal squamous cell carcinoma who have received chemo-immunotherapy before surgery. During standard tumor removal, surgeons will carefully label and analyze each lymph node station to see which ones still contain cancer. The goal is to map …

This study is testing whether artificial intelligence can predict how well stomach cancer patients will respond to chemotherapy given before surgery. Researchers will collect CT scans, ultrasound images, and blood samples from 300 patients with locally advanced gastric cancer. Us…

This study looks at how certain cancers develop in people with HIV and what factors might increase their risk. Researchers will analyze medical data from 1,000 HIV-positive adults to track which types of cancer occur most often and why. The goal is to improve early detection and …

This study investigates why some stomach cancers do not respond to a standard chemotherapy combination (FLOT) plus the immunotherapy drug durvalumab. Researchers will analyze tumor samples and blood from 250 patients with operable stomach or gastroesophageal junction cancer. By m…

This study investigates whether substances in saliva, specifically interleukin-6 levels and certain gene variations, can indicate whether oral cancer has spread to lymph nodes in the neck. Researchers will collect saliva samples from adults with oral squamous cell carcinoma befor…

This study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study investigates why colorectal adenomas (precancerous polyps) sometimes return after being surgically removed. Researchers will collect tissue samples from 30 patients and use advanced genetic sequencing to compare polyps that recur with those that do not. The goal is to …

This study is testing whether a blood test can locate where colorectal cancer has returned or spread after surgery. Researchers are analyzing genetic markers in the blood to build a model that predicts whether a recurrence is local or distant. The goal is to improve early detecti…

This study will include about 2,748 people with breast, gynecologic, or pancreatic cancer. Researchers want to see if adding patient-reported outcomes—like symptoms, preferences, and travel distance—to tumor board discussions helps doctors make better treatment decisions. The goa…

This study explores whether a special imaging technique called parenchymal blood volume (PBV) imaging can detect changes in blood flow within liver tumors after giving a drug called nitroglycerin. The drug is commonly used for heart conditions but may temporarily increase blood f…

This study looks at people who have had certain types of colon polyps (serrated lesions) removed. It aims to find out why some of them later develop new advanced growths in the colon. By tracking 750 adults over time, researchers hope to identify risk factors that could help doct…

This study explores whether combining artificial intelligence analysis of tumor tissue with special blood tests (liquid biopsy) can more accurately predict if colon cancer will return after surgery. Researchers will follow 400 adults with stage II or III colon cancer for up to fi…

The EXPAND study is a research project that will enroll 440 adults with and without pancreatic conditions to understand why type 2 diabetes varies so much from person to person. Researchers will collect data on metabolism, genetics, and pancreas health to identify distinct diabet…

This study looks at whether emotional distress before treatment affects how well immunotherapy works in people with locally advanced stomach or gastroesophageal junction cancer. Researchers will measure distress using questionnaires and track tumor response after surgery. The goa…

This study will examine whether certain workplace chemicals or tasks increase the risk of biliary tract and pancreatic cancers. Researchers will compare detailed work histories of 210 cancer patients from two earlier trials with healthy volunteers. The goal is to identify occupat…

This study tests a new one-click autofocus system for magnifying endoscopy, which uses computer vision to automatically focus the camera during stomach exams. Researchers will compare it to the standard manual focus method in 93 patients with stomach diseases. The goal is to see …

This study follows about 2000 people with colorectal cancer to track their health over time, including survival, disease progression, and side effects from treatments. Researchers aim to understand how the disease behaves in real-world settings, outside of controlled clinical tri…

This observational study will use bedside ultrasound to measure the diaphragm—the main breathing muscle—in 120 adults with liver cirrhosis and compare them to healthy volunteers. Researchers want to see if cirrhosis weakens the diaphragm and if removing fluid from the belly impro…

This study looks at whether sleep patterns—like duration, quality, and heart rate during sleep—are linked to how well stomach cancer responds to immunotherapy before surgery. Researchers will monitor sleep non-invasively in 120 patients with locally advanced gastric or gastroesop…

This study looks at whether it's safe to skip mechanical bowel preparation (the drink that cleans out your colon) before colon surgery. Currently, the best practice combines that drink with antibiotics to prevent infections. The trial will compare two groups: one getting the drin…

This study tests a new surgical method for removing the splenic flexure during laparoscopic surgery for left-sided colorectal cancer. It compares the new technique (inferior mesenteric artery first with complete medial approach) to traditional methods. The goal is to see if it is…

This study aims to create a score that predicts the risk of infection within 30 days after a liver transplant. Researchers will collect blood samples from 279 liver transplant patients before and after surgery to measure immune markers. The goal is to combine these markers with o…

This study will send different types of WhatsApp messages to 235,000 people in Chile who are due for cancer or chronic disease screenings. Researchers want to see if the way a message is worded (basic, risk-focused, or peace-of-mind) and whether it mentions one test or both tests…

This study tests whether a digitally supported prehabilitation program is feasible for patients awaiting major surgery for cancers of the pancreas, liver, stomach, or esophagus. The program includes supervised exercise, nutritional counseling, psychological support, and digital t…

This study will follow 57 people having minimally invasive colon surgery where the removed tissue is taken out through the rectum instead of a new abdominal cut. Researchers want to see how often this technique injures the internal anal sphincter muscle and how it affects bowel c…

This study looks at whether a tumor's DNA repair status (MMR) changes how well the presence of cancer cells in lymph vessels predicts spread to lymph nodes in stomach cancer. Researchers will review medical records of 3,000 patients who had surgery. The goal is to improve risk as…

This study will follow 200 people with colorectal cancer and healthy controls to explore how genes, blood sugar, and immune responses are connected. Researchers will analyze blood and tissue samples to find shared genetic factors that may influence both cancer and diabetes. The g…

This study will collect and analyze medical records from about 4,000 adults diagnosed with liver cancer (hepatocellular carcinoma) in Middle Eastern and North African countries between 2015 and 2023. Researchers want to understand what causes the cancer, how it is treated, and wh…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study is testing whether a green dye called indocyanine green (ICG) can help surgeons see and remove lymph nodes that contain cancer during laparoscopic colon cancer surgery. About 25 adults with colon cancer will receive the dye injected around the tumor and into a vein. Th…

This study looks at whether the type of stapler used to reconnect the bowel after colorectal cancer surgery affects the risk of a leak. About 600 adults having planned surgery will be observed, but their treatment won't change. The goal is to see if newer staplers are safer than …

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study looks back at data from 562 people who received a liver transplant for liver cancer (hepatocellular carcinoma) at hospitals in France, Canada, and Belgium. The goal is to create a better scoring system that considers tumor shrinkage before transplant, cancer growth whi…

This study will test a new way to create CT images for people with colon cancer. The method uses deep learning to make the images clearer. Researchers will compare the quality of these new images to standard ones. The goal is to see if this technique helps doctors see tumors bett…

This study looks at how decision counseling affects people who get a positive result on the Shield blood test for colorectal cancer. Researchers want to see if counseling helps reduce confusion and increases the chance of getting a follow-up colonoscopy. About 350 adults aged 45-…

This study looks at why some patients develop blood clots after pancreatic surgery that also involves removing a piece of a major vein. Researchers will collect information from over 1,000 patients across many hospitals to see how surgical techniques and blood-thinning medication…

This study will follow 800 people, including those with chronic pancreatitis, pancreatic cancer, and healthy volunteers, to learn why some pancreatitis patients later get pancreatic cancer. Participants give blood samples and health info; some may also provide tissue samples. Res…

This study looks at how removing part or all of the pancreas changes blood sugar control in adults who already have diabetes and need pancreatic surgery. Researchers will track 408 patients over time to see if diabetes gets worse depending on how much pancreas is removed. The goa…

This study looks at whether it is safe to give patients their own salvaged red blood cells back during surgery for pancreatic cancer. About 40 adults will take part, and researchers will track infections and other complications within the first week after surgery. The goal is to …

This study will compare treatment recommendations made by a large language model (AI) with those made by a team of cancer experts for 180 people with rectal cancer. The AI will analyze de-identified patient information and suggest a treatment plan. The goal is to see how often th…

This study aims to see if using a patient's genetic signature to choose chemotherapy can improve outcomes for people with borderline resectable pancreatic cancer. About 367 participants will receive standard chemotherapy, and researchers will track how long they live without majo…